TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE
The present invention provides chromium compounds which possess the ability to improve insulin sensitization, glucose tolerance, blood lipid metabolism, lean body mass, bioavailability, and safety as compared to chromium nicotinate, chromium picolinate and chromium histidine. These compounds are scr...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | BAGCHI, DEBASIS CHIEN, XIAOMING, XU |
| description | The present invention provides chromium compounds which possess the ability to improve insulin sensitization, glucose tolerance, blood lipid metabolism, lean body mass, bioavailability, and safety as compared to chromium nicotinate, chromium picolinate and chromium histidine. These compounds are screened in terms of solubility, in vitro insulin sensitization, stability, and absorption as compared to chromium nicotinate, chromium picolinate and chromium histidine. The most promising chromium compounds are tested for their animal in vivo bioavailability, glucose metabolism, lipid metabolism and acute toxicity.
La présente invention concerne des composés à base de chrome ayant la capacité d'améliorer la sensibilisation à l'insuline, la tolérance au glucose, le métabolisme lipidique du sang, la masse du corps excluant la graisse, la biodisponibilité, et la sécurité par rapport au nicotinate de chrome, au picolinate de chrome et à l'histidine de chrome. Ces composés sont sélectionnés en termes de solubilité, sensibilisation à l'insuline in vitro, stabilité, et absorption par rapport au nicotinate de chrome, au picolinate de chrome et à l'histidine de chrome. Les composés à base de chrome les plus prometteurs sont testés pour leur disponibilité, leur métabolisme du glucose, le métabolisme lipidique et la toxicité aiguë sur des animaux in vivo. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2007121312A9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2007121312A9</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2007121312A93</originalsourceid><addsrcrecordid>eNrjZLANCfIMc_Rx9QtRcPYI8vf1DPVVcPb3DfAP9XMJ1oEwgz1DPP39ghUc_VwUfF1DPPxdghX83RRCg115GFjTEnOKU3mhNDeDsptriLOHbmpBfnxqcUFicmpeakl8uL-RgYG5oZGhsaGRo6UxcaoA_dIq-w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE</title><source>esp@cenet</source><creator>BAGCHI, DEBASIS ; CHIEN, XIAOMING, XU</creator><creatorcontrib>BAGCHI, DEBASIS ; CHIEN, XIAOMING, XU</creatorcontrib><description>The present invention provides chromium compounds which possess the ability to improve insulin sensitization, glucose tolerance, blood lipid metabolism, lean body mass, bioavailability, and safety as compared to chromium nicotinate, chromium picolinate and chromium histidine. These compounds are screened in terms of solubility, in vitro insulin sensitization, stability, and absorption as compared to chromium nicotinate, chromium picolinate and chromium histidine. The most promising chromium compounds are tested for their animal in vivo bioavailability, glucose metabolism, lipid metabolism and acute toxicity.
La présente invention concerne des composés à base de chrome ayant la capacité d'améliorer la sensibilisation à l'insuline, la tolérance au glucose, le métabolisme lipidique du sang, la masse du corps excluant la graisse, la biodisponibilité, et la sécurité par rapport au nicotinate de chrome, au picolinate de chrome et à l'histidine de chrome. Ces composés sont sélectionnés en termes de solubilité, sensibilisation à l'insuline in vitro, stabilité, et absorption par rapport au nicotinate de chrome, au picolinate de chrome et à l'histidine de chrome. Les composés à base de chrome les plus prometteurs sont testés pour leur disponibilité, leur métabolisme du glucose, le métabolisme lipidique et la toxicité aiguë sur des animaux in vivo.</description><language>eng ; fre</language><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS ; ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM ; CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2008</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20080717&DB=EPODOC&CC=WO&NR=2007121312A9$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20080717&DB=EPODOC&CC=WO&NR=2007121312A9$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BAGCHI, DEBASIS</creatorcontrib><creatorcontrib>CHIEN, XIAOMING, XU</creatorcontrib><title>TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE</title><description>The present invention provides chromium compounds which possess the ability to improve insulin sensitization, glucose tolerance, blood lipid metabolism, lean body mass, bioavailability, and safety as compared to chromium nicotinate, chromium picolinate and chromium histidine. These compounds are screened in terms of solubility, in vitro insulin sensitization, stability, and absorption as compared to chromium nicotinate, chromium picolinate and chromium histidine. The most promising chromium compounds are tested for their animal in vivo bioavailability, glucose metabolism, lipid metabolism and acute toxicity.
La présente invention concerne des composés à base de chrome ayant la capacité d'améliorer la sensibilisation à l'insuline, la tolérance au glucose, le métabolisme lipidique du sang, la masse du corps excluant la graisse, la biodisponibilité, et la sécurité par rapport au nicotinate de chrome, au picolinate de chrome et à l'histidine de chrome. Ces composés sont sélectionnés en termes de solubilité, sensibilisation à l'insuline in vitro, stabilité, et absorption par rapport au nicotinate de chrome, au picolinate de chrome et à l'histidine de chrome. Les composés à base de chrome les plus prometteurs sont testés pour leur disponibilité, leur métabolisme du glucose, le métabolisme lipidique et la toxicité aiguë sur des animaux in vivo.</description><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS</subject><subject>ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM</subject><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2008</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLANCfIMc_Rx9QtRcPYI8vf1DPVVcPb3DfAP9XMJ1oEwgz1DPP39ghUc_VwUfF1DPPxdghX83RRCg115GFjTEnOKU3mhNDeDsptriLOHbmpBfnxqcUFicmpeakl8uL-RgYG5oZGhsaGRo6UxcaoA_dIq-w</recordid><startdate>20080717</startdate><enddate>20080717</enddate><creator>BAGCHI, DEBASIS</creator><creator>CHIEN, XIAOMING, XU</creator><scope>EVB</scope></search><sort><creationdate>20080717</creationdate><title>TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE</title><author>BAGCHI, DEBASIS ; CHIEN, XIAOMING, XU</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2007121312A93</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2008</creationdate><topic>ACYCLIC OR CARBOCYCLIC COMPOUNDS</topic><topic>ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM</topic><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>BAGCHI, DEBASIS</creatorcontrib><creatorcontrib>CHIEN, XIAOMING, XU</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BAGCHI, DEBASIS</au><au>CHIEN, XIAOMING, XU</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE</title><date>2008-07-17</date><risdate>2008</risdate><abstract>The present invention provides chromium compounds which possess the ability to improve insulin sensitization, glucose tolerance, blood lipid metabolism, lean body mass, bioavailability, and safety as compared to chromium nicotinate, chromium picolinate and chromium histidine. These compounds are screened in terms of solubility, in vitro insulin sensitization, stability, and absorption as compared to chromium nicotinate, chromium picolinate and chromium histidine. The most promising chromium compounds are tested for their animal in vivo bioavailability, glucose metabolism, lipid metabolism and acute toxicity.
La présente invention concerne des composés à base de chrome ayant la capacité d'améliorer la sensibilisation à l'insuline, la tolérance au glucose, le métabolisme lipidique du sang, la masse du corps excluant la graisse, la biodisponibilité, et la sécurité par rapport au nicotinate de chrome, au picolinate de chrome et à l'histidine de chrome. Ces composés sont sélectionnés en termes de solubilité, sensibilisation à l'insuline in vitro, stabilité, et absorption par rapport au nicotinate de chrome, au picolinate de chrome et à l'histidine de chrome. Les composés à base de chrome les plus prometteurs sont testés pour leur disponibilité, leur métabolisme du glucose, le métabolisme lipidique et la toxicité aiguë sur des animaux in vivo.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2007121312A9 |
| source | esp@cenet |
| subjects | ACYCLIC OR CARBOCYCLIC COMPOUNDS ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T05%3A51%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BAGCHI,%20DEBASIS&rft.date=2008-07-17&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2007121312A9%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |